Drugs Made In America Acquisition cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 5 quarters of results from Mar 2025 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.25M | 2.29M | 2.18M | 0.21M | 1.73M |
| Cash from Operations | -0.25M | -0.11M | -0.06M | -0.13M | |
| Change in Working Capital | |||||
| Change in Accured Expenses | 0.06M | 0.01M | 0.16M | -0.08M | |
| Other Working Capital Changes | 0.07M | -0.02M | -0.02M | -0.02M | |
| Investing Activities | |||||
| Cash from Investing Activities | -231.15M | ||||
| Financing Activities | |||||
| Other financing activities | 3.20M | ||||
| Debt Issuance and Repayment | |||||
| Long-Term Debt Issuances | 0.90M | ||||
| Misc. | |||||
| Cash from Financing Activities | 231.40M | 0.11M | 0.06M | 0.13M | |
| Change in Cash | -428.00 | -101.00 | -105.00 | 0.01M | |
| Free Cash Flow | -0.25M | -0.11M | -0.06M | -0.13M | |
| Net Cash Flow | -428.00 | -101.00 | -105.00 | 0.01M |